HuR regulates β-tubulin isotype expression in ovarian cancer

Cancer Research

Volumn 70, Issue 14, 2010, Pages 5891-5900

  Raspaglio, Giuseppina ^a   De Maria, Ilaria ^a   Filippetti, Flavia ^a   Martinelli, Enrica ^a   Zannoni, Gian Franco ^a   Prislei, Silvia ^a   Ferrandina, Gabriella ^b   Shahabi, Shohreh ^c   Scambia, Giovanni ^a   Ferlini, Cristiano ^b,c  

^a CATHOLIC UNIVERSITY   (Italy)

^b DANBURY HOSPITAL   (United States)

^c CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BETA TUBULIN; HU ANTIGEN; HUR PROTEIN; MESSENGER RNA; PROTEIN TUBB 3; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CANCER SURVIVAL; COMPUTER MODEL; CONTROLLED STUDY; CYTOSKELETON; DNA FLANKING REGION; GENE SILENCING; HUMAN; HUMAN CELL; HYPOGLYCEMIA; IMMUNOPRECIPITATION; OVARY CANCER; POLYSOME; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; RNA SEQUENCE; STAINING; UNTRANSLATED REGION;

3' UNTRANSLATED REGIONS; ADENOCARCINOMA; ANTIGENS, SURFACE; CELL LINE, TUMOR; FEMALE; HUMANS; HYPOGLYCEMIA; IMMUNOHISTOCHEMISTRY; OVARIAN NEOPLASMS; RNA, MESSENGER; RNA-BINDING PROTEINS; TUBULIN;

EID: 77955048655     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-4656     Document Type: Article

References (24)

1. Kyrgiou M, Salanti G, Pavlidis N, Paraskevaidis E, Ioannidis JP. Survival benefits with diverse chemotherapy regimens for ovarian cancer: metaanalysis of multiple treatments. J Natl Cancer Inst 2006;98:1655-63. (Pubitemid 44811648)
2. Semenza GL. HIF-1 and tumor progression: pathophysiology and therapeutics. Trends Mol Med 2002;8:S62-7.
3. Kavallaris M, Kuo DYS, Burkhart CA, et al. Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific β-tubulin isotypes. J Clin Invest 1997;100:1282-93. (Pubitemid 27386315)
4. Derry WB, Wilson L, Khan IA, Luduena RF, Jordan MA. Taxol differentially modulates the dynamics of microtubules assembled from unfractionated and purified β-tubulin isotypes. Biochemistry 1997;36:3554-62. (Pubitemid 27143509)
5. Ferrandina G, Zannoni GF, Martinelli E, et al. Class III {β}-tubulin overexpression is a marker of poor clinical outcome in advanced ovarian cancer patients. Clin Cancer Res 2006;12:2774-9. (Pubitemid 43752116)
6. Seve P, Dumontet C. Is class III β-tubulin a predictive factor in patients receiving tubulin-binding agents? Lancet Oncol 2008;9:168-75.
7. Raspaglio G, Filippetti F, Prislei S, et al. Hypoxia induces class III β-tubulin gene expression by HIF-1α binding to its 3′ flanking region. Gene 2008;409:100-8.
8. Mozzetti S, Iantomasi R, De MI, et al. Molecular mechanisms of patupilone resistance. Cancer Res 2008;68:10197-204.
9. Tenenbaum SA, Lager PJ, Carson CC, Keene JD. Ribonomics: identifying mRNA subsets in mRNP complexes using antibodies to RNA-binding proteins and genomic arrays. Methods 2002;26:191-8.
10. Lin NY, Lin CT, Chen YL, Chang CJ. Regulation of tristetraprolin during differentiation of 3T3-1 preadipocytes. FEBS J 2007;274:867-78.
11. Hovland R, Campbell G, Pryme I, Hesketh J. The mRNAs for cyclin A, c-myc and ribosomal proteins L4 and S6 are associated with cytoskeletal-bound polysomes in HepG2 cells. Biochem J 1995;310:193-6.
12. Paradiso A, Mangia A, Chiriatti A, et al. Biomarkers predictive for clinical efficacy of Taxol-based chemotherapy in advanced breast cancer. Ann Oncol 2005;16 Suppl 4:iv14-9.
13. Urano N, Fujiwara Y, Doki Y, et al. Clinical significance of class III β-tubulin expression and its predictive value for resistance to docetaxel-based chemotherapy in gastric cancer. Int J Oncol 2006;28:375-81.
14. Lee KM, Cao D, Itami A, et al. Class III β-tubulin, a marker of resistance to paclitaxel, is overexpressed in pancreatic ductal adenocarcinoma and intraepithelial neoplasia. Histopathology 2007;51:539-46. (Pubitemid 47437824)
15. Seve P, Isaac S, Tredan O, et al. Expression of class III {β}-tubulin is predictive of patient outcome in patients with non-small cell lung cancer receiving vinorelbine-based chemotherapy. Clin Cancer Res 2005;11:5481-6. (Pubitemid 41060824)
16. Gullino PM. In vivo utilization of oxygen and glucose by neoplastic tissue. Adv Exp Med Biol 1976;75:521-36.
17. Abdelmohsen K, Lal A, Kim HH, Gorospe M. Posttranscriptional orchestration of an anti-apoptotic program by HuR. Cell Cycle 2007;6:1288-92. (Pubitemid 47327958)
18. Hinman MN, Lou H. Diverse molecular functions of Hu proteins. Cell Mol Life Sci 2008;65:3168-81.
19. Yen TJ, Machlin PS, Cleveland DW. Autoregulated instability of β-tubulin mRNAs by recognition of the nascent amino terminus of β-tubulin. Nature 1988;334:580-5.
20. Meng Z, King PH, Nabors LB, et al. The ELAV RNA-stability factor HuR binds the 5′-untranslated region of the human IGF-IR transcript and differentially represses cap-dependent and IRES-mediated translation. Nucleic Acids Res 2005;33:2962-79. (Pubitemid 41518704)
21. Mozzetti S, Ferlini C, Concolino P, et al. Class III β-tubulin over-expression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients. Clin Cancer Res 2005;11:298-305. (Pubitemid 40075808)
22. Erkinheimo TL, Lassus H, Sivula A, et al. Cytoplasmic HuR expression correlates with poor outcome and with cyclooxygenase 2 expression in serous ovarian carcinoma. Cancer Res 2003;63:7591-4. (Pubitemid 37466678)
23. Hostetter C, Licata LA, Witkiewicz A, et al. Cytoplasmic accumulation of the RNA binding protein HuR is central to tamoxifen resistance in estrogen receptor positive breast cancer cells. Cancer Biol Ther 2008;7:1496-506.
24. Brosens LA, Keller JJ, Pohjola L, et al. Increased expression of cytoplasmic HuR in familial adenomatous polyposis. Cancer Biol Ther 2008;7:424-7. (Pubitemid 351847061)